Home UAE Abu Dhabi Hayat Biotech bolsters Abu Dhabi’s life sciences hub ambitions The city serves as a secure and efficient gateway for global distribution, particularly in the healthcare industry by Gulf Business June 8, 2023 Image: Supplied Abu Dhabi-based Hayat Biotech hosted national and international healthcare experts, academics and representatives from the department of health to discuss the future of the UAE healthcare system and the role of Abu Dhabi on the international stage. The panel discussion, titled Revolutionizing Life Sciences from Abu Dhabi, stimulated the exchange of knowledge and experiences and explored priorities and key areas of activations and collaboration. Naser Al Yammahi, deputy CEO of Hayat Biotech, in his keynote address, said that the company is passionately committed to supporting the Department of Health – Abu Dhabi’s (DoH) ambitious vision of establishing the city as a preeminent global hub for biotechnology and life sciences. “Our unwavering focus is on collaborating with international pharmaceutical companies to facilitate the localisation of their productions and help them achieve their growth objectives. Our ultimate goal is to create a lasting impact on the sector at a global level, transforming the landscape of biotechnology and life sciences for generations to come,” said Al Yammahi. Hayat Biotech’s cutting-edge biotechnology facilities located in Abu Dhabi and Belgrade, Serbia, boasting a combined annual production capacity of 230 million vials, play a crucial role in the company’s global ambitions. Naser Al Yammahi, Deputy CEO of Hayat Biotech, has discussed the importance of the Revolution in Life Sciences from Abu Dhabi session, supporting the development of the health sector and enhancing partnerships to advance research and innovation in life sciences. — مكتب أبوظبي الإعلامي (@ADMediaOffice) June 8, 2023 The company has successfully partnered with international companies, who have relocated their production to facilities in the UAE. Hayat Biotech is positioning itself as the preferred destination of choice for biopharma companies seeking to establish local and regional production capabilities in the country. Abu Dhabi boost its life science hub appeal Meanwhile, owing to its strategic geographical location, Abu Dhabi serves as a secure and efficient gateway for global distribution, particularly in the healthcare industry. The UAE authorities have taken proactive measures by implementing diverse programs and initiatives, fostering an attractive environment for international players to establish in the region. Leveraging its remarkable advancements in healthcare, the UAE has solidified its position as a prominent hub for medication logistics, transportation, and distribution, playing an active role in improving global health outcomes. Hayat Biotech, in collaboration with IROS, has established itself as a preferred partner for clinical studies in the healthcare industry, due to its expertise and ongoing commitment to conducting clinical trials. The company is continuously developing new and innovative biopharma products that address unmet medical needs or improve upon existing treatments, in addition to the eight clinical trials that have already been conducted across the UAE. “Conducting clinical trials in Abu Dhabi provide access to diverse patient populations that may not be available in other regions,” said Dr Nawal Al Kaabi, Senior Advisor at Hayat Biotech. “This diversity can be crucial in testing the efficacy and safety of drugs in different ethnic groups and people with different health conditions, which can lead to more accurate results and better treatments.” Its commitment to medical science has made it a trusted partner for biopharma companies looking to conduct clinical studies and bring new products to market. Hayat Biotech is playing a critical role in driving this progress as Abu Dhabi continues to establish itself as a leading hub for research, development and production of biopharma. Read: Role of biotechnology and life sciences in UAE’s healthcare ambitions Tags Abu Dhabi biopharma Hayat Biotech Healthcare 0 Comments You might also like Novartis Gulf’s Mohamed Ezz Eldin on the region’s key healthcare trends Abu Dhabi’s Etihad Airways posts 66% rise in nine-month profit AD Ports Group marks Q3 performance with net profit of Dhs445m UAE’s ADNOC Gas boosts capex to $15bn on booming LNG market